

| | | | | | | | |
|---|--|--|-----------------------------|----------------------------|--------------|--------------------|---------------------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | | SERIAL NO. | | 10/533,734 | |
| | | | | FILING DATE | | May 4, 2005 | |
| | | | | APPLICANT | | Ertl | |
| | | | | GROUP | | 1648 | |
| | | | | EXAMINER | | Kinsey | |
| | | | | ATTORNEY DOCKET NO. | | PG5023USw | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initials | | Patent Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | Document Number | Publication Date | Country | Class | Subclass | Translation Yes No |
| | | 99/016884 | 08 April 1999 | WO | | | |
| | | 02/099101 | 12 Dec 2002 | WO | | | |
| | | 02/0220080 | 21 Mar 2002 | WO | | | |
| | | 04/041851 | 21 May 2004 | WO | | | |
| | | 1015596 | 30 Aug 2006 | EP | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) | | | | | | | |
| | | Asjo et al., Phase 1 trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy, AIDS Res Hum Retroviruses 18(18):1357-1365 (Dec 2002) | | | | | |
| | | Azad et al., Large-scale production and characterization of recombinant HIV-1 Nef, J. General Virology, 75:651-655 (1994) | | | | | |
| | | Berzofsky, Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization, Biotechnol. Ther. 2(1-2): 123-135 (1991) | | | | | |
| | | Betts et al., Optimal antigens for HIV vaccines based on CD8 + T response, protein length, and sequence variability, DNA Cell Biology 21(9):665-670 (Sept. 2002) | | | | | |
| | | Cosma et al., Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals, Vaccine 22(1), 21-29 (Dec 2003) | | | | | |
| | | Deml et al, Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein, J. Virology 75(22);10991-11001 (2001) | | | | | |
| | | Estaquier et al., Comprehensive delineation of antigenic and immunogenic properties of peptides derived from the nef HIV-1 regulatory protein, Vaccine 11(11):1083-1092 (1993) | | | | | |
| | | Gahery-Segard et al., Long term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+T cell epitopes recognized, J. Virol. 77(20):11220-11231 (Oct. 2003) | | | | | |
| | | Gahery-Segard et al., Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine, J. Virol. 74(4):1694-1703 (Feb. 2000) | | | | | |
| | | Hinkula et al., Recognition of prominent viral epitopes induced by immunization with HIV-1 regulatory genes, J. Virology, 71(7), 5528-5539 (1997) | | | | | |
| | | Johnson and Walker, Cytotoxic T lymphocytes in human immunodeficiency virus infection: responses to structural protein, Curr Top Microbiol Immunol. 189:35-63 (1994) | | | | | |
| | | Kmieciak et al., Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by G/P-92 fusion protein expressing highly immunogenic Gag P17/p24 and Pol p51 antigens, J Human Virology 4(6):306-316 (2001) | | | | | |
| | | Letvin et al., Progress in the development of Nan HIV-1 Vaccine, Science 280:1875 (1998) | | | | | |
| | | Pialoux et al., Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers, AIDS 15(10):1239-1249 (July 2001) | | | | | |

| | | |
|---|--|---|
| | | Robert Guroff, HIV Regulatory and accessory proteins, new targets for vaccine development, DNA and Cell Biology, 21(9): 597-598 (Sept 2002) |
| | | Zur Megede et al., Increased expression and immunogenicity of sequence modified HIV-1 gag gene, J. Virology 74:2628 (2000) |
| | | |
| | | |
| | | |
| EXAMINER | | DATE CONSIDERED |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | | |